title: Monocyte and interferon based therapy for the treatment of ovarian cancer.
abstract: Cytokines and cells of the innate immune system have been shown to be critical regulators in the elimination, equilibrium and escape of malignant cells. Despite in vitro and in vivo evidence, components of the innate immune system have shown limited efficacy in the treatment of ovarian cancer. Intraperitoneal immunotherapies are a promising field that has not yet been fully explored in ovarian cancer. Cytokine immunotherapy using interferon alpha (IFN-α) and interferon gamma (IFN-γ) has predominantly been used intraperitoneally in ovarian cancer, with promising results. Early studies also showed that autologous monocytes infused into the peritoneum have anti-tumor properties. Combination therapies have been shown to be more effective in treating cancer than mono-therapies. Based on these observations the combination of cell therapy with cytokine therapy may provide a unique strategy for the treatment of chemotherapy resistant solid cancers.
authors.affiliation: Cytokine Biology Section, National Institute of Allergy and Infectious Diseases, National Institute of Health, USA. Electronic address: Daniel.green2@nih.gov.
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Green
authors.affiliation: Medical Oncology Branch, NCI, 10 Center DR, RM 12N226, Bethesda, MD 20814, USA. Electronic address: ana.nunes@nih.gov.
authors.forename: Ana T
authors.initials: AT
authors.lastname: Nunes
authors.affiliation: Women's Malignancy Branch, NCI, NIH, Translational Genomics Section, 10 Center DR RM 3B43A, Bethesda, MD 20892, USA. Electronic address: ca180n@nih.gov.
authors.forename: Christina M
authors.initials: CM
authors.lastname: Annunziata
authors.affiliation: Cytokine Biology Section, National Institute of Allergy and Infectious Diseases, National Institute of Health, USA. Electronic address: kz15m@nih.gov.
authors.forename: Kathryn C
authors.initials: KC
authors.lastname: Zoon
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D017708:Leukocyte Transfusion; D009000:Monocytes; D010051:Ovarian Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
chemical_list: C573415:IFNG protein, human; D016898:Interferon-alpha; D007371:Interferon-gamma
keywords: Immunotherapy; Interferon alpha; Interferon gamma; Monocyte; Ovarian cancer